Myelodysplastic syndrome classification: Difference between revisions

	Myelodysplastic syndrome Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Myelodysplastic syndrome from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
Electrocardiogram
Chest X Ray
Echocardiography and Ultrasound
CT
MRI
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Myelodysplastic syndrome classification On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
Powerpoint slides
Images
American Roentgen Ray Society Images of Myelodysplastic syndrome classification All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Myelodysplastic syndrome classification
CDC on Myelodysplastic syndrome classification
Myelodysplastic syndrome classification in the news
Blogs on Myelodysplastic syndrome classification
Directions to Hospitals Treating Myelodysplastic syndrome
Risk calculators and risk factors for Myelodysplastic syndrome classification

← Older edit Newer edit →

VisualWikitext

Revision as of 21:16, 13 December 2018

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Nawal Muazam M.D.[2]

Overview

Myelodysplastic syndrome may be classified into several subtypes based on the French-American-British (FAB) classification and World Health Organization the (WHO) classification methods.

Classification

French-American-British (FAB) Classification

Myelodysplastic syndrome may be classified according to the French-American-British classification into five groups: Refractory anemia, refractory anemia with ring sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia.^[1]^[2]
The table below lists FAB classification for myelodysplastic syndrome:^[1]^[2]


Name	Description

Refractory anemia	Less than 5% primitive blood cells (myeloblasts) in the bone marrow and pathological abnormalities primarily seen in red blood cell precursors.
Refractory anemia with ring sideroblasts (RARS)	Less than 5% myeloblasts in the bone marrow, but distinguished by the presence of ringed sideroblasts which may compose greater than 15% of red blood cell precursor in the marrow.
Refractory anemia with excess blasts (RAEB)	5-20% myeloblasts in the marrow
Refractory anemia with excess blasts in transformation (RAEB-T)	21-30% myeloblasts in the marrow (>30% blasts is defined as acute myeloid leukemia)
Chronic myelomonocytic leukemia (CMML)	Less than 20% myeloblasts in the bone marrow and greater than 1*109/L monocytes in peripheral blood

WHO Classification

Myelodysplastic syndromes may be classified according to the WHO classification method into eight subtypes: Refractory anemia, refractory cytopenia with unilineage dysplasia, refractory anemia with ring sideroblasts, refractory cytopenia with multilineage dysplasia, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, refractory cytopenia of childhood, and unclassifiable myelodysplastic syndrome.^[2]^[3]
The table below lists World Health Organiztion classification for myelodysplastic syndrome:^[2]^[3]


Old system	New system

Refractory anemia	Refractory cytopenia with unilineage dysplasia
Refractory anemia with ringed sideroblasts	Refractory anemia with ring sideroblasts
	Refractory cytopenia with multilineage dysplasia
Refractory anemia with excess blasts	Refractory anemias with excess blasts I and II
Refractory anemia with excess blasts in transformation I–IV	5q - syndrome
Chronic myelomonocytic leukemia	Myelodysplastic-myeloproliferative overlap syndromes
	Refractory cytopenia of childhood
	Unclassifiable myelodysplastic syndrome

References

↑ ^1.0 ^1.1 Classification of myelodysplastic syndrome. Radiopaedia (2015). http://radiopaedia.org/articles/myelodysplastic-syndrome. Accessed on December 7, 2015
↑ ^2.0 ^2.1 ^2.2 ^2.3 Pathologic systems of myelodysplastic syndrome. National Cancer Institute (2015). http://www.cancer.gov/types/myeloproliferative/hp/myelodysplastic-treatment-pdq/#link/_204_toc. Accessed on December 7, 2015
↑ ^3.0 ^3.1 World Health Organization classification of myelodysplastic syndrome. Wikipedia (2015). https://en.wikipedia.org/wiki/Myelodysplastic_syndrome. Accessed on December 8, 2015

Template:WikiDoc Sources

[radiopaedia-1] 1.0 ^1.1 Classification of myelodysplastic syndrome. Radiopaedia (2015). http://radiopaedia.org/articles/myelodysplastic-syndrome. Accessed on December 7, 2015

[cancergov2-2] 2.0 ^2.1 ^2.2 ^2.3 Pathologic systems of myelodysplastic syndrome. National Cancer Institute (2015). http://www.cancer.gov/types/myeloproliferative/hp/myelodysplastic-treatment-pdq/#link/_204_toc. Accessed on December 7, 2015

[wikiWHO-3] 3.0 ^3.1 World Health Organization classification of myelodysplastic syndrome. Wikipedia (2015). https://en.wikipedia.org/wiki/Myelodysplastic_syndrome. Accessed on December 8, 2015

[1]

[2]

[3]

@@ Line 3: / Line 3: @@
 {{CMG}};{{AE}} {{NM}}
 ==Overview==
-Myelodysplastic syndrome may be classified into several subtypes based on the [[French-American-British classification|French-American-British (FAB) classification]] and [[World Health Organization]] the (WHO) classification methods.<ref name=radiopaedia>Classification of myelodysplastic syndrome. Radiopaedia (2015). http://radiopaedia.org/articles/myelodysplastic-syndrome. Accessed on December 7, 2015</ref><ref name=cancergov2>Pathologic systems of myelodysplastic syndrome. National Cancer Institute (2015). http://www.cancer.gov/types/myeloproliferative/hp/myelodysplastic-treatment-pdq/#link/_204_toc. Accessed on December 7, 2015</ref><ref name=wikipedia>French-American-British (FAB) classification of myelodysplastic syndrome. Wikipedia (2015). https://en.wikipedia.org/wiki/Myelodysplastic_syndrome. Accessed on December 7, 2015</ref><ref name=wikiWHO>World Health Organization classification of myelodysplastic syndrome. Wikipedia (2015). https://en.wikipedia.org/wiki/Myelodysplastic_syndrome. Accessed on December 8, 2015</ref>
+Myelodysplastic syndrome may be classified into several subtypes based on the [[French-American-British classification|French-American-British (FAB) classification]] and [[World Health Organization]] the (WHO) classification methods.
 ==Classification==
 ===French-American-British (FAB) Classification===
-*Myelodysplastic syndrome may be classified according to the [[French-American-British classification|French-American-British classification]] into five groups: Refractory [[anemia]], refractory anemia with ring sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia.<ref name=radiopaedia>Classification of myelodysplastic syndrome. Radiopaedia (2015). http://radiopaedia.org/articles/myelodysplastic-syndrome. Accessed on December 7, 2015</ref><ref name=cancergov2>Pathologic systems of myelodysplastic syndrome. National Cancer Institute (2015). http://www.cancer.gov/types/myeloproliferative/hp/myelodysplastic-treatment-pdq/#link/_204_toc. Accessed on December 7, 2015</ref><ref name=wikipedia>French-American-British (FAB) classification of myelodysplastic syndrome. Wikipedia (2015). https://en.wikipedia.org/wiki/Myelodysplastic_syndrome. Accessed on December 7, 2015</ref>
+*Myelodysplastic syndrome may be classified according to the [[French-American-British classification|French-American-British classification]] into five groups: Refractory [[anemia]], refractory anemia with ring sideroblasts, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, and chronic myelomonocytic leukemia.<ref name="radiopaedia">Classification of myelodysplastic syndrome. Radiopaedia (2015). http://radiopaedia.org/articles/myelodysplastic-syndrome. Accessed on December 7, 2015</ref><ref name="cancergov2">Pathologic systems of myelodysplastic syndrome. National Cancer Institute (2015). http://www.cancer.gov/types/myeloproliferative/hp/myelodysplastic-treatment-pdq/#link/_204_toc. Accessed on December 7, 2015</ref>
-*The table below lists [[French-American-British classification|FAB]] classification for myelodysplastic syndrome:<ref name=radiopaedia>Classification of myelodysplastic syndrome. Radiopaedia (2015). http://radiopaedia.org/articles/myelodysplastic-syndrome. Accessed on December 7, 2015</ref><ref name=cancergov2>Pathologic systems of myelodysplastic syndrome. National Cancer Institute (2015). http://www.cancer.gov/types/myeloproliferative/hp/myelodysplastic-treatment-pdq/#link/_204_toc. Accessed on December 7, 2015</ref><ref name=wikipedia>French-American-British (FAB) classification of myelodysplastic syndrome. Wikipedia (2015). https://en.wikipedia.org/wiki/Myelodysplastic_syndrome. Accessed on December 7, 2015</ref>
+*The table below lists [[French-American-British classification|FAB]] classification for myelodysplastic syndrome:<ref name="radiopaedia">Classification of myelodysplastic syndrome. Radiopaedia (2015). http://radiopaedia.org/articles/myelodysplastic-syndrome. Accessed on December 7, 2015</ref><ref name="cancergov2">Pathologic systems of myelodysplastic syndrome. National Cancer Institute (2015). http://www.cancer.gov/types/myeloproliferative/hp/myelodysplastic-treatment-pdq/#link/_204_toc. Accessed on December 7, 2015</ref>
 {| style="border: 0px; font-size: 90%; margin: 3px; width: 1000px"
-|valign=top|
+| valign="top" |
 |+
-! style="background: #4479BA; width: 250px; color: #FFFFFF;"|'''Name'''
+! style="background: #4479BA; width: 250px; color: #FFFFFF;" |'''Name'''
-! style="background: #4479BA; width: 600px; color: #FFFFFF;"|'''Description'''
+! style="background: #4479BA; width: 600px; color: #FFFFFF;" |'''Description'''
 |-
-| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''Refractory anemia'''|| style="padding: 5px 5px; background: #F5F5F5;" |
+| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align="center" | '''Refractory anemia'''|| style="padding: 5px 5px; background: #F5F5F5;" |
 :* Less than 5% primitive blood cells (myeloblasts) in the bone marrow and pathological abnormalities primarily seen in red blood cell precursors.
 |-
-| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''Refractory anemia with ring sideroblasts (RARS)'''|| style="padding: 5px 5px; background: #F5F5F5;"|
+| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align="center" | '''Refractory anemia with ring sideroblasts (RARS)'''|| style="padding: 5px 5px; background: #F5F5F5;" |
 :* Less than 5% myeloblasts in the bone marrow, but distinguished by the presence of ringed sideroblasts which may compose greater than 15% of red blood cell precursor in the marrow.
 |-
-| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''Refractory anemia with excess blasts (RAEB)'''|| style="padding: 5px 5px; background: #F5F5F5;"|
+| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align="center" | '''Refractory anemia with excess blasts (RAEB)'''|| style="padding: 5px 5px; background: #F5F5F5;" |
 :* 5-20% myeloblasts in the marrow
 |-
-| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''Refractory anemia with excess blasts in transformation (RAEB-T)'''|| style="padding: 5px 5px; background: #F5F5F5;" |
+| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align="center" | '''Refractory anemia with excess blasts in transformation (RAEB-T)'''|| style="padding: 5px 5px; background: #F5F5F5;" |
 :*21-30% myeloblasts in the marrow (>30% blasts is defined as acute myeloid leukemia)
 |-
-| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''Chronic myelomonocytic leukemia (CMML)'''|| style="padding: 5px 5px; background: #F5F5F5;" |
+| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align="center" | '''Chronic myelomonocytic leukemia (CMML)'''|| style="padding: 5px 5px; background: #F5F5F5;" |
 :*Less than 20% myeloblasts in the bone marrow and greater than 1*109/L monocytes in peripheral blood
 |}
 ===WHO Classification===
-*Myelodysplastic syndromes may be classified according to the WHO classification method into eight subtypes: Refractory anemia, refractory cytopenia with unilineage dysplasia, refractory anemia with ring sideroblasts, refractory cytopenia with multilineage dysplasia, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, refractory cytopenia of childhood, and unclassifiable myelodysplastic syndrome.<ref name=cancergov2>Pathologic systems of myelodysplastic syndrome. National Cancer Institute (2015). http://www.cancer.gov/types/myeloproliferative/hp/myelodysplastic-treatment-pdq/#link/_204_toc. Accessed on December 7, 2015</ref><ref name=wikiWHO>World Health Organization classification of myelodysplastic syndrome. Wikipedia (2015). https://en.wikipedia.org/wiki/Myelodysplastic_syndrome. Accessed on December 8, 2015</ref>
+*Myelodysplastic syndromes may be classified according to the WHO classification method into eight subtypes: Refractory anemia, refractory cytopenia with unilineage dysplasia, refractory anemia with ring sideroblasts, refractory cytopenia with multilineage dysplasia, refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, refractory cytopenia of childhood, and unclassifiable myelodysplastic syndrome.<ref name="cancergov2">Pathologic systems of myelodysplastic syndrome. National Cancer Institute (2015). http://www.cancer.gov/types/myeloproliferative/hp/myelodysplastic-treatment-pdq/#link/_204_toc. Accessed on December 7, 2015</ref><ref name="wikiWHO">World Health Organization classification of myelodysplastic syndrome. Wikipedia (2015). https://en.wikipedia.org/wiki/Myelodysplastic_syndrome. Accessed on December 8, 2015</ref>
-*The table below lists World Health Organiztion classification for myelodysplastic syndrome:<ref name=cancergov2>Pathologic systems of myelodysplastic syndrome. National Cancer Institute (2015). http://www.cancer.gov/types/myeloproliferative/hp/myelodysplastic-treatment-pdq/#link/_204_toc. Accessed on December 7, 2015</ref><ref name=wikiWHO>World Health Organization classification of myelodysplastic syndrome. Wikipedia (2015). https://en.wikipedia.org/wiki/Myelodysplastic_syndrome. Accessed on December 8, 2015</ref>
+*The table below lists World Health Organiztion classification for myelodysplastic syndrome:<ref name="cancergov2">Pathologic systems of myelodysplastic syndrome. National Cancer Institute (2015). http://www.cancer.gov/types/myeloproliferative/hp/myelodysplastic-treatment-pdq/#link/_204_toc. Accessed on December 7, 2015</ref><ref name="wikiWHO">World Health Organization classification of myelodysplastic syndrome. Wikipedia (2015). https://en.wikipedia.org/wiki/Myelodysplastic_syndrome. Accessed on December 8, 2015</ref>
 {| style="border: 0px; font-size: 90%; margin: 3px; width: 800px"
-|valign=top|
+| valign="top" |
 |+
-! style="background: #4479BA; width: 200px; color: #FFFFFF;"|'''Old system'''
+! style="background: #4479BA; width: 200px; color: #FFFFFF;" |'''Old system'''
-! style="background: #4479BA; width: 200px; color: #FFFFFF;"|'''New system'''
+! style="background: #4479BA; width: 200px; color: #FFFFFF;" |'''New system'''
 |-
-| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''[[Refractory anemia]]'''
+| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align="center" | '''[[Refractory anemia]]'''
-| style="padding: 5px 5px; background: #F5F5F5;" align=center |
+| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
 Refractory cytopenia with unilineage dysplasia
 |-
-| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''[[Refractory anemia with ringed sideroblasts]]'''
+| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align="center" | '''[[Refractory anemia with ringed sideroblasts]]'''
-| style="padding: 5px 5px; background: #F5F5F5;" align=center |
+| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
 Refractory anemia with ring sideroblasts
 |-
-| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center |
+| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align="center" |
-|style="padding: 5px 5px; background: #F5F5F5;" align=center |
+| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
 Refractory cytopenia with multilineage dysplasia
 |-
-| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''[[Refractory anemia with excess blasts]]'''
+| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align="center" | '''[[Refractory anemia with excess blasts]]'''
-| style="padding: 5px 5px; background: #F5F5F5;" align=center |
+| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
 Refractory anemias with excess blasts I and II
 |-
-| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''[[Refractory anemia with excess blasts in transformation]] I–IV '''
+| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align="center" | '''[[Refractory anemia with excess blasts in transformation]] I–IV '''
-| style="padding: 5px 5px; background: #F5F5F5;" align=center |
+| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
 q - syndrome
 |-
-| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center | '''[[Chronic myelomonocytic leukemia]]'''
+| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align="center" | '''[[Chronic myelomonocytic leukemia]]'''
-| style="padding: 5px 5px; background: #F5F5F5;" align=center |
+| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
 Myelodysplastic-myeloproliferative overlap syndromes
 |-
-| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center |
+| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align="center" |
-| style="padding: 5px 5px; background: #F5F5F5;" align=center |
+| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
 Refractory cytopenia of childhood
 |-
-|style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align=center |
+| style="padding: 5px 5px; background: #DCDCDC; font-weight: bold" align="center" |
-| style="padding: 5px 5px; background: #F5F5F5;" align=center |
+| style="padding: 5px 5px; background: #F5F5F5;" align="center" |
 Unclassifiable myelodysplastic syndrome
 |}